Posaconazole is widely used for prophylaxis against invasive fungal infections in patients undergoing myeloablative therapy. Disseminated fusariosis is a serious invasive mold infection in such patients. Preclinical and clinical studies indicate activity of posaconazole against Fusarium. We describe two cases of disseminated fusariosis that occurred despite posaconazole prophylaxis.
liposomal AmB and oral voriconazole 3 weeks after the diagnosis of disseminated fusariosis. She was readmitted 17 days later for consolidation chemotherapy. AmB was stopped due to worsening renal function, and voriconazole was continued. Chemotherapy with cytarabine was administered once her renal function stabilized, and she was discharged. Unfortunately, 11 days after her second hospital discharge, she presented with hypotension, dyspnea, dehydration, and renal failure, and she died within 24 h of overwhelming pneumococcal septic shock.
Case report 2. A 42-year-old male was diagnosed with AML after presenting with a scrotal abscess, extreme leukocytosis, anemia, and thrombocytopenia. After emergent leukapheresis, he underwent incision and drainage of scrotal and dental abscesses with complete maxillary dental extraction and was placed on imipenem, metronidazole, and vancomycin based on the results of susceptibility testing on cultures from his scrotal abscess (Bacteroides spp., coagulase-negative staphylococci, diphtheroids, and peptostreptococci). Vancomycin and metronidazole were discontinued after 13 and 5 days, respectively, whereas imipenem was continued. Standard induction chemotherapy for AML was administered with cytarabine and idarubicin. He received fluconazole (200 mg orally daily) for 7 days for unidentified yeast (not Cryptococcus) cultured from his sputum and Candida albicans cultured from his dental abscesses. After that, he was placed on posaconazole (200 mg by mouth three times daily) for antifungal prophylaxis. Reinduction with high-dose cytarabine was attempted after a day 14 bone marrow biopsy showed persistent AML. Two weeks after starting posaconazole, the patient complained of pain and swelling in the left nasolabial region. Culture from a nasal swab grew Fusarium species. Posaconazole was then stopped, and he was placed on liposomal AmB (5 mg/kg every 24 h). Imipenem was changed to cefepime plus ciprofloxacin after blood cultures grew Pseudomonas aeruginosa resistant to imipenem, and G-CSF was added. He also developed a pimple-like lesion on his left chest that was biopsied, cultures of which grew Fusarium. Voriconazole (6 mg/kg i.v. for 2 doses 12 h apart, followed by 4 mg/kg every 12 h) was then substituted for AmB. Shortly thereafter, vancomycin was resumed due to Enterococcus faecalis bacteremia. The patient underwent maxillary antrostomy and left inferior turbinate resection due to persistent left maxillary sinusitis, and cultures of his nasal tissues again grew Fusarium species, with MICs of 2 g/ml for AmB and voriconazole but Ͼ16 g/ml for posaconazole (by the broth microdilution method). Invasive fungal sinusitis was histopathologically confirmed in biopsy specimens. The antibacterials were stopped, and voriconazole was continued. Second-look endoscopic sinus surgery with exploration and debridement of the left nasal cavity again showed hyphae in the necrotic debris. Salvage chemotherapy with cladribine, cytarabine, and mitoxantrone with G-CSF priming (CLAG-M) was administered due to persistent AML. After this, the patient developed neutropenic fever and septic shock. Blood cultures grew Pseudomonas aeruginosa again. Vancomycin, ciprofloxacin, and AmB were all restarted, and ceftazidime was added, while voriconazole and G-CSF were continued. Computerized tomography suggested invasive fungal disease in the nose and sinuses and also showed multiple brain lesions. Despite all efforts, his clinical condition progressively deteriorated; he remained profoundly pancytopenic and died a few days later.
The epidemiology of invasive fungal infections (IFI) is changing (5, 8) . Fusarium species are important plant pathogens that can cause a wide array of human infections. Keratitis and onychomycosis are the most common infections in immunocompetent hosts, but immunocompromised patients may develop endophthalmitis, sinusitis, pneumonia, skin lesions, fungemia, and disseminated infections. Patients with prolonged and profound neutropenia and/or severe T-cell immunodeficiency are at high risk for disseminated fusariosis (6). Indeed, among immunocompromised patients, invasive fusariosis represents the second most common invasive mold infection (after aspergillosis). In a retrospective review of 84 patients with hematologic malignancies and invasive fusariosis, multivariate predictors of poor outcome were persistent neutropenia and use of corticosteroids. Only 18 patients (21%) remained alive 90 days after the diagnosis of fusariosis, no patient with both risk factors survived, and the actuarial survival rate for patients with persistent neutropenia was only 4% (7) . Treatments include AmB, voriconazole, and posaconazole, complemented by removal of infected catheters, surgical debulking of infected tissues when feasible, G-CSF treatment, and G-CSF-stimulated granulocyte transfusions (6) .
Posaconazole is an expanded-spectrum triazole antifungal recommended by the National Comprehensive Cancer Network (NCCN) for prophylaxis against fungal infections in patients undergoing chemotherapy for AML or myelodysplastic syndrome (MDS) who are or are anticipated to be neutropenic and in HSCT recipients with graft-versus-host disease (GVHD) (11), based on two large, randomized phase III controlled trials (1, 12) . Its broad spectrum of in vitro activity, oral route of administration, lack of a need for dose adjustment in patients with renal or hepatic dysfunction, and safety profile have made posaconazole a popular choice for prophylaxis (10) . However, the emergence of resistant mold infections is almost inevitable (5) .
There are reports of the successful treatment of fusariosis with posaconazole. In the largest series, 21 patients with proven or probable fusariosis, who had failed or were intolerant of standard antifungal therapy, received salvage treatment with posaconazole (9) . An underlying hematologic malignancy was present in 76%. A successful outcome occurred in 10 (48%), which contrasts sharply with the 21% 90-day survival rate seen in the first-line setting (7) , suggesting that these patients may have had a better prognosis simply by their surviving long enough to receive a second treatment (6) .
The absorption of posaconazole can be quite unpredictable, with large variations in bioavailability based on the number of daily doses, fed versus fasting state, and meal composition (10) . A case of disseminated fusariosis that developed and progressed on posaconazole was reported (3) . In that case, successful therapy was achieved by changing therapy because subtherapeutic posaconazole levels were measured even at the most bioavailable 200-mg four-times-daily dose. Indeed, therapeutic monitoring has been suggested for posaconazole, and a specific recommendation has been proposed by the FDA but is not part of the current FDA-approved labeling (10) or common practice. Evaluation of our cases is limited by the lack of therapeutic drug monitoring.
Meta-analyses of antifungal prophylaxis in patients with hematologic malignancies show that prophylaxis decreases IFI and IFI-related mortality but not overall mortality (4) . The large trial of posaconazole prophylaxis in HSCT recipients with GVHD (12) noted the emergence of Candida species isolates with reduced in vitro susceptibility to posaconazole and/or other triazoles. Our experience shows that life-threatening Fusarium infections may occur in immunocompromised patients on prophylactic posaconazole. As such, preemptive and empirical therapy approaches to the management of IFI may remain warranted in patients receiving posaconazole prophylaxis (2) .
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